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Dermatological problems are not usually related to intensive medicine because they are considered to have a low impact on the
evolution of critical patients. Despite this, dermatological manifestations (DMs) are relatively frequent in critically ill patients. In
rare cases, DMs will be the main diagnosis and will require intensive treatment due to acute skin failure. In contrast, DMs can be a
reflection of underlying systemic diseases, and their identification may be key to their diagnosis. On other occasions, DMs are
lesions that appear in the evolution of critical patients and are due to factors derived from the stay or intensive treatment. Lastly,
DMs can accompany patients and must be taken into account in the comprehensive pathology management. Several factors must
be considered when addressing DMs: on the one hand, the moment of appearance, morphology, location, and associated
treatment and, on the other hand, aetiopathogenesis and classification of the cutaneous lesion. DMs can be classified into 4 groups:
life-threatening DMs (uncommon but compromise the patient’s life); DMs associated with systemic diseases where skin lesions
accompany the pathology that requires admission to the intensive care unit (ICU); DMs secondary to the management of the
critical patient that considers the cutaneous manifestations that appear in the evolution mainly of infectious or allergic origin; and
DMs previously present in the patient and unrelated to the critical process.(is review provides a characterization of DMs in ICU
patients to establish a better identification and classification and to understand their interrelation with critical illnesses.
1. Introduction
Dermatological problems have received limited attention
within the field of intensive care medicine, probably be-
cause they are considered within a specialty with a large
outpatient component and rarely are serious and because
of the limited impact they have on the prognosis of critical
patients. Less than 0.5% of patients requiring admission to
an intensive care unit (ICU) do so because of a primary
dermatological problem [1]. However, and more generally,
dermatological manifestations (DMs) in critical patients
are relatively frequent and can be markers of extracuta-
neous pathology. In a previous study, we observed that
10.4% of patients admitted to an ICU had some type of
DM [2], and a study by Agrawal observed DMs in up to
42.2% of critically ill patients [3]. Identifying these
manifestations can be key in the recognition of an un-
derlying disease. Examples include skin manifestations in
meningococcal sepsis, skin as an expression of dissemi-
nated candidiasis, or ecthyma gangrenosum in Pseudo-
monas aeruginosa infection [4, 5]. Other times, DMs
reflect secondary effects of drugs or devices [6, 7], prob-
lems derived from procedures [8], or simply a patient’s
critical situation [9, 10]. DMs can be presented in a highly
varied way, and a definitive diagnosis often requires the
collaboration of a dermatologist.
(e objective of this review is to describe the most
frequent DMs found in critically ill patients. (ermal in-
juries and necrotizing fasciitis, which constitute differenti-
ated entities, are not included.(is review consists of several
sections: we will analyse the differentiating characteristics
and the classification of DMs in critical patients, review
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published series, describe schematically the different types of
DMs, and close with the conclusions.
1.1. Differentiating Characteristics of Dermatological Mani-
festations in Critical Patients. (e management of critical
patients requires a multidisciplinary evaluation and man-
agement as a fundamental part of their treatment. Rarely are
patients admitted due to a dermatological disease; however,
the DMs that appear during the evolution of the patients and
that require treatment are relatively frequent [11]. Prolonged
immobilization, insufficient nutritional support, impaired
tissue perfusion, changes in body temperature, hygiene
challenges, use of multiple drugs, and invasive processes may
facilitate the development of DMs in ICU patients [12].
To these circumstances, we must add the lack of
symptoms due to an altered state of consciousness, either by
the use of sedative drugs or by neurological impairment,
which makes communication with the patients difficult.
(ere is little literature that specifically addresses DMs in the
critical patient context, and there is no homogenous clas-
sification available.
Patients respond to the aggression of critical illnesses
with profound changes at the immunological, endocrine,
and vascular levels that results in impairments in tissue
perfusion and changes in the microcirculation of the skin
that alter the signs and symptoms of cutaneous lesions [13].
DMs that can be identified in Intensive Care Medicine
have been classified in different ways. In some cases, a
classification based on morphology or lesions [14] has been
used according to whether the DM required the care of a
dermatologist or only an intensivist [15]. We believe, con-
curring with other authors, that the classification that should
be used in critical patients must have a dermatological base,
but it should also include groups with differentiating
characteristics in the diagnosis, treatment, and evolution
during admission to the ICU [16–18].
In Table 1, a classification is proposed that includes the
particularities of ICU patients. (ere are 4 main groups: life-
threatening DMs (corresponding in the literature with the
term primary lesions); DMs associated with systemic dis-
eases (may indicate an underlying disease); DMs secondary
to the management of the critical patient (divided into in-
fectious, drug reactions, and secondary to devices); and
previous DMs (named coincidental in previous studies
[16, 17]) that, if not identified, could hinder or confuse the
main diagnosis of the patient.
1.2. Review of Published Series on Dermatological Manifes-
tations in the ICU. Table 2 shows the published works that
include the follow-up of series of patients admitted to the
ICU where the main DMs are analysed. Some studies focus
on DMs associated with ICU treatment [15, 19]; others, such
as studies on paediatric patients, include a morphological
classification attributable to the importance of exanthematic
childhood diseases.
It is difficult to compare different publications due to the
lack of homogeneity in the DM classification; therefore, we
have adapted the results obtained to the classification
devised by Dunnil et al. [16] in a classic study that, with some
modifications, has been maintained in our publications and
in those made by Awal et al. [17, 18]. (e advantage offered
by this classification is that it groups DMs based on the
situation of the critical patients without ignoring the origin
of the DMs. Different studies show that dermatological
admission is infrequent but that DMs usually accompany the
evolution of critical patients either in the context of a sys-
temic disease or adding to their main pathological process,
influencing stay, and mortality.
(e differences attributed to the country of origin of the
different articles determine the type of lesions identified, as is
the case in the study by Prashanth and Pai, in which 64% of
patients had Dengue haemorrhagic fever [20]. We also
verified the importance of the year of publication of the
study. In our case, we went from 12 patients with DMs
secondary to meningococcal meningitis in 1999 to 1 case in
2013, a situation that we attribute to the broad use of a
meningococcal vaccine [2].
As limitations of the different studies, except for George
[1], the studies were carried out in a single centre and were
mainly retrospective, which hinders the generalization of the
results. Furthermore, the type of DM studied differs among
the authors. Some studies included necrotizing fasciitis [1] or
pressure ulcers [18], which we exclude from classification
because they have very well-defined characteristics and are
treated independently in most cases.
All the studies described collaboration with a derma-
tologist specialist, either as a principal physician or as a
consultant.
2. Classification of Dermatological
Manifestations in Intensive Medicine
2.1. Life-*reatening Dermatological Manifestations.
Table 1: Classification of dermatological manifestations in critical
patients.
Classification of dermatological manifestations in critical patients
1. Dermatological manifestations of life-threatening skin diseases
1.1. Immune-bullous diseases
1.2. Generalized pustular psoriasis
1.3. Erythroderma
2. Severe cutaneous adverse drug reactions
2.1. Toxic shock syndrome
2.2. Staphylococcal scalded skin syndrome
3. Dermatological manifestations of underlying systemic diseases
3.1. Purpura fulminans
3.2. Cutaneous lesions caused by direct vascular injury
3.3. Calciphylaxis
3.4. Cutaneous vasculitis
3.5. Connective tissue diseases
4. Dermatological manifestations as a consequence critical illness
4.1. Dermatological disorders of infectious origin
4.2. Dermatological disorders from drug reactions
4.3. Dermatological disorders secondary to devices
4.4. Dermatological disorders related pressure injuries
4.5. Dermatological disorders induced by vasopressor drugs
5. Previous dermatological manifestations
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(ese DMs require admission to the ICU. (ey are rare (as
seen in Table 2) but severe and are associated with high
mortality. (ey cause loss or deterioration of cutaneous
functions, leading to an imbalance and failure of the cuta-
neous barrier, defined as acute skin failure [21]. Destruction
of the stratum corneum, the outermost layer of the epi-
dermis, causes the loss of fluids, proteins, and electrolytes,
immunological dysfunction with the consequent risk of
infection, thermoregulatory impairment, and a hyper-
catabolic state.
Within this group, we include various entities such as
immunobullous diseases, generalized pustular psoriasis,
erythroderma, severe cutaneous adverse reactions (SCARs),
and infectious diseases such as scalded skin syndrome.
2.1.1. Immunobullous Skin Diseases. Immunobullous dis-
eases represent a heterogeneous group of entities in which
the typical lesion is a blister due to the loss of adhesion
between intraepidermal cells or between the basal kerati-
nocytes to the basement membrane; according to the degree
of systemic repercussions, these diseases may require critical
treatment, with pemphigus vulgaris as its potentially most
serious form.(e bullous pemphigoid, more common in the
elderly, usually has a self-limited course with low mortality
rate.
(e paraneoplastic pemphigus (PNP) is a variety of
pemphigus with differential characteristics. (e PNP is
an autoimmune blistering syndrome that can affect multiple
organs other than skin and is closely related with benign
or malignant tumours especially lymphomatoid and
hematologic malignances. Patients with PNP can develop
life-threatening restrictive bronchiolitis obliterans that is
irreversible with lung transplant being the only possible
alternative. PNP treatment should be focused on the
eradication of the associated tumour process. Cutaneous
manifestations usually have a poor response to treatment,
being better than those associated with benign processes
such as thymoma or Castleman’s disease [22].
(e pemphigus group has desmogleins as the main
antigen. Autoantibodies directed against these proteins in-
hibit their adhesive function, causing loss of the intercellular
binding of keratinocytes.
(e pemphigus group of blistering autoimmune diseases
is characterized by mucocutaneous blisters that break easily
and become erosions. Upon examination, a positive
Nikolsky’s sign (skin detachment when applying lateral
pressure on the skin near an ampoule) is typical, and the
diagnosis is made by skin biopsy. Treatment should combine
skin care with anti-inflammatory and immunosuppressive
aetiological treatment with corticosteroids, immunoglobu-
lins, and, in recent years, mycophenolate mofetil; biological
therapies such as rituximab have been added with satis-
factory results [23].
2.1.2. Generalized Pustular Psoriasis. Generalized pustular
psoriasis (GPP), also known as Von Zumbusch disease, is an
inflammatory skin disorder with multisystemic and po-
tentially fatal affectation. Recently, a genetic mutation in
IL36RN (key component of the innate immune system) has
been suggested as the basis of generalized pustular disease
[24, 25]. It is characterized by the appearance of erythem-
atous plaques with sterile pustular lesions followed by ex-
tensive desquamative areas and associated with a systemic
inflammatory response syndrome. (e severity of the
condition usually requires systemic treatment such as
methotrexate or ciclosporin. (e best pathophysiological
knowledge of the disease justifies the use of new therapies
with the ability to block tumour necrosis factor α or other
involved interleukins [26, 27].
2.1.3. Erythroderma. Erythroderma is an exfoliative der-
matitis characterized by erythema that affects more than
90% of the skin surface with a variable degree of desqua-
mation. It is a cutaneous manifestation of various skin
diseases (psoriasis and atopic dermatitis), drug reactions
(allopurinol, carbamazepine, ciprofloxacin, etc.), or malig-
nant processes (T-lymphoma or paraneoplastic phenomena)
[28]. Patchy areas of erythroderma are observed and evolve
to affect most of the skin surface accompanied by a variable
degree of scaling.(e skin appears as intense red, bright, dry,
and scaly and is often accompanied by pruritus and
ectropion. Frequently, the clinical presentation indicates the
underlying disease, with psoriasis being the most frequent
cause followed by drug reactions [29]. Skin biopsy may be
useful to determine the aetiology, although sometimes the
findings are nonspecific and may require multiple biopsies.
Erythroderma treatment is based on controlling the un-
derlying disease, removing external contributing factors, and
providing supportive therapy. At the systemic level, ade-
quate hydration must be maintained with fluid replacement,
electrolyte correction, and meticulous skin care [30].
2.1.4. Severe Cutaneous Adverse Reactions (SCARs).
SCARs are unpredictable and infrequent but have high
morbidity and mortality. Adverse drug reactions alter the
immune response and cause extensive epidermolysis. (e
main conditions that encompass noninfectious SCARs are
Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis
(TEN), and drug-induced hypersensitivity syndrome/drug
reaction with eosinophilia and systemic symptoms (DISH-
DRESS) [31].
SJS and TEN are considered the same entity, with dif-
ferent degrees of severity. (ey are characterized by ery-
thema with extensive epidermal detachment and mucous
membrane erosion. (e classification is based on the per-
centage of affected skin area. Epidermolysis of less than 10%
is defined as SJS, detachment between 10 and 30% is clas-
sified as SJS/TEN overlap, and detachment greater than 30%
is classified as TEN [32].
(e first clinical manifestation is usually fever and
malaise followed by generalized erythema with the ap-
pearance of blisters that break easily and erosion in mucous
membranes of the mouth, eyes, and genital area. In the most
extensive forms, erosion and necrosis can affect the con-
junctiva, bronchi, trachea, intestine, and kidney, with a
mortality ranging between 25 and 30%. (e severity of the
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clinical picture can be determined using the SCORTEN
severity scale, designed as a predictor of mortality from toxic
epidermal necrolysis. It uses 7 easy-to-measure items: age,
presence of malignancy, tachycardia, degree of skin de-
tachment, and plasma levels of urea, blood glucose, and
bicarbonate [33].
Some medications alter the immune response, together
with a genetic susceptibility that causes the development of
SCARs [32]. Sulfonamides are the most frequently impli-
cated drugs, followed by cephalosporins, quinolones, im-
idazoles, and anticonvulsants such as carbamazepine and
lamotrigine (Figure 1). In recent years, specific human
leucocyte antigen (HLA) genotypes have been associated
with the appearance of SCARs with the use of carbamaze-
pine [34].
DISH-DRESS is a drug-induced, multisystemic, and
infrequent reaction that occurs between 3 and 6 weeks after
the administration of a drug and has been associated with
the reactivation of herpes virus 6. (e main causative agents
are anticonvulsants (carbamazepine, phenytoin, phenobar-
bital, mexiletine, and lamotrigine), allopurinol, and sulfa-
salazine. It is defined by a generalized, long-lasting
maculopapular rash or any other skin rash that progresses
occasionally to erythroderma, accompanied by fever,
lymphadenopathy, and impaired liver function as the most
common organ involvement [35].
Diagnosis by skin biopsy is the only method to confirm
the nature of the skin reaction [36]. (e main differentiating
diagnosis is scalded skin syndrome caused by Staphylococcus
species and other cutaneous autoimmune skin diseases such
as pemphigus vulgaris and pemphigoid of the mucous
membrane. Treatment should include immediate with-
drawal of the suspect drug and life-support therapy [37].
2.1.5. Toxic Shock Syndrome. Toxic shock syndrome (TSS) is
a rare, acute Gram positive infection characterized by fever,
malaise, gastrointestinal symptoms, confusion, weakness,
and refractory hypotension associated with diffuse, red,
macular rash that can involve both skin and mucous
membranes, conjunctival hyperaemia, and “strawberry
tongue.” Desquamation occurs 1-2 weeks after disease onset.
TSS is typically caused by exotoxins produced by Staphy-
lococcus aureus or group A Streptococcus [38]. Some cases
have been related to the use of vaginal tampons and vaginal
colonization by Staphylococcus facilitating the production of
exotoxin. Nonmenstrual cases may result around surgical
site, burns, nasal packing, postinfluenza pneumonia, post-
partum infections, or insulin pump infusion sites, or no
source may be identified. Patients should be managed in
accordance with sepsis guidelines. Antibiotics should be
initiated against S. aureus and S. pyogenes and an aggressive
source control is mandatory, which may include surgical
debridement, removal of invasive devices, or vaginal ex-
amination in the case of suspected menstrual TSS [39].
2.1.6. Staphylococcal Scalded Skin Syndrome.
Staphylococcal scalded skin syndrome (SSSS) is a bullous
disease that is potentially life-threatening due to infection
with Staphylococcus aureus, which produces an exfoliative
exotoxin [40]. (e bacterium is located in mucous mem-
branes, and its toxin spreads through the bloodstream,
causing intraepidermal detachment due to breakage of the
desmoglein 1 complex far from the initial focus (positive
Nikolsky’s sign). (is pathology can affect any age, but it is
more frequent in children under 5 years of age; however,
when it affects adults, it is usually more serious, with
mortality up to 60%. It can be confused with TEN, but its
main differences are that it does not usually affect mucous
membranes, is not related to drug exposure, and has a
different histological pattern. In the treatment, the initiation
of the appropriate antibiotic drug early is essential [41].
2.2. Dermatological Disorders Associated with Systemic
Diseases. DMs can precede, accompany, or follow the
evolution of a systemic disease. A wide variety of diseases can
present DMs. (e DMs that we can most frequently find in
the field of intensive care are secondary to peripheral vas-
cular damage produced in the context of a systemic un-
derlying disease or are manifestations of an immune disease
such as vasculitis or connective tissue diseases.
2.2.1. Purpura Fulminans. Venous insufficiency with cuta-
neous infarction and disseminated intravascular coagulation
can appear in the context of severe sepsis; however, it can
also be due to a congenital deficit of protein C or protein
Figure 2: Purpura fulminans: haemorrhagic necrosis of the skin in
the patient’s foot.
Figure 1: Toxic epidermal necrolysis (TEN): detachment of the top
layer of skin of the upper extremity.
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S. Classically, it has been related to the most serious forms of
meningococcal sepsis, but it can also be present in sepsis due
to Haemophilus, Streptococcus, Staphylococcus, or less fre-
quent germs such as Rickettsia, especially in anaesthetic
patients [42–44].
(e characteristic lesions are very well-delimited pete-
chiae or ecchymoses, usually located on the trunk and ex-
tremities that can progress to extensive areas of cutaneous
necrosis, especially in acral areas; development is favoured
by the simultaneous administration of vasopressor drugs
(Figure 2). Histology shows endothelial damage with areas of
thrombosis in the vascular wall [45]. Skin lesion biopsy
rarely reveals the bacteria responsible for the disease.
Treatment is aimed at controlling the septic process.
2.2.2. Cutaneous Lesions due to Direct Vascular Injury.
Some systemic infectious processes present cutaneous
manifestations due to direct vascular injury such as ecthyma
gangrenosum, Janeway spots, or Osler nodules. (e gan-
grenous ecthyma, related to systemic infection by Pseudo-
monas aeruginosa, manifests as a maculopapular lesion with
a central vesicle that ruptures and leaves an ulcer with a
painful necrotic bottom. Osler nodules and Janeway spots
are produced by septic microemboli in the context of
bacterial endocarditis. Osler’s nodules are small, reddish,
painful, raised lesions that appear on the thumb, fingers, and
toes; Janeway’s spots, on the other hand, are small hae-
morrhagic, nonpainful lesions located on palms and soles
(Figure 3). Treatment is directed to the germ responsible for
the septic process [46].
2.2.3. Calciphylaxis. Calciphylaxis is a rare multifactorial
cutaneous vascular disease with predilection for patients
with end-stage renal disease characterized by occlusion of
microvessels in the subcutaneous adipose tissue and dermis.
Calciphylaxis causes painful cutaneous lesions and is fre-
quently accompanied by tactile hyperesthesia. (e skin
manifestations include necrotic ulcers, livedo racemosa,
haemorrhagic patches, haemorrhagic bullae, and indurated
plaques. A dusky discoloration of the skin indicates and area
of imminent necrosis [47]. Sepsis originating from these
resultant wounds is considered the most common cause of
death. Although skin manifestations dominate the clinical
presentation, calciphylaxis is likely a systemic disorder and
extraskeletal calcifications are often found on imaging
studies. Skin biopsy is the standard method for confirmation
suspected calciphylaxis. However, the biopsy is not needed
in patients with typical lesions and end-stage renal disease.
Treatment should be aimed at controlling pain and wound
care with removal of necrotic tissue. Other therapeutic
options such as sodium thiosulfate or bisphosphonates have
proven effective in some cases [48].
2.2.4. Cutaneous Vasculitis. Vasculitis is a group of complex
and disabling diseases that are characterized by an in-
flammatory infiltrate in or around blood vessels that causes
vascular damage. Skin involvement is common, and its form
of presentation depends on the size of the affected vessel.(e
classification of vasculitis, much debated in recent years, is
based on the size of the affected vessel, the pathogenesis, and
the main organ involved [49]. We distinguish 2 types of
cutaneous vasculitis: small vessel vasculitis and single-organ
vasculitis. Clinically, the typical lesion is palpable purpura;
however, other lesions such as ulcers, blisters, or livedo
reticularis may be associated. Palpable purpura is very
suggestive of small vessel vasculitis and affects arterioles,
capillaries, and postcapillary venules. Skin biopsy is the gold
diagnostic standard and allows differentiation from other
nonvasculitic processes with similar clinical manifestation
due to vessel wall dysfunction or their occlusion, as observed
in coagulation diseases or purpura fulminans.
(e most typical presentation is leukocytoclastic vas-
culitis or small vessel vasculitis restricted to the skin. (e
most frequent manifestation is palpable purpura (approxi-
mately 2–10mm in diameter) located in the lower ex-
tremities and buttocks with a symmetrical distribution. On
occasion, arthralgias and/or arthritis may also appear with
general symptoms such as fever, malaise, anorexia, and
myalgias. Systemic involvement is rare, and if it occurs, it is
of mild intensity [50].
(e treatment of this vasculitic process is symptomatic.
In cases with extensive skin involvement, the use of corti-
costeroids may be effective. Severe forms may require
corticoids at higher doses, dapsone, and even azathioprine or
rituximab [51].
Another type of small vessel vasculitis is ANCA-asso-
ciated vasculitis (AAV) that includes granulomatosis with
polyangiitis, microscopic polyangiitis (MPA), and eosino-
philic granulomatosis with polyangiitis (EGPA). AAV can
affect multiple organs systems and the patient may need to
be admitted to the ICU. Granulomatosis with polyangiitis,
previously known as Wegener’s granulomatosis, is defined
as a necrotizing granulomatous inflammation of the upper
and lower respiratory tracts with necrotizing vasculitis of
small and medium-size vessels and usual renal involvement.
MPA belongs to the systemic vasculitis and the major organs
involved are the kidneys and the lungs. EGPA, previously
called Churg–Strauss syndrome, typically occurs in patients
with preexisting asthma and involves the skin, lungs, heart,
and peripheral nerves.
(e most common skin manifestation of ANCA-asso-
ciated vasculitis is palpable purpura located on limbs. Other
Figure 3: Janeway lesions: erythematous macular painless rashes
distributed along the tips of the fingers.
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manifestations include livedo reticularis, nodules, urticarial
lesions, and skin ulcers with necrosis [52].
Cutaneous manifestations in vasculitis are not exclusive
to those affecting the small vessel. Medium and large vessel
vasculitis can show DMs even though the affected vessels are
not in the skin [53]. In large vessel vasculitis such as
Takayasu arteritis and giant-cell arteritis, Raynaud’s phe-
nomenon, digital gangrene, or unilateral digital clubbing, is
typical, although in Europe and North America it is more
frequent to manifest as acute inflammatory nodules or er-
ythema nodosum-like lesions. Two major types of medium
vessel vasculitis are Kawasaki disease and polyarteritis
nodosa (PAN). Kawasaki disease is characterized by a
mucocutaneous lymph node and polymorphous exanthema
varying from macular to maculopapular or morbilliform.
(e most frequent DMs of PAN are, in the order of fre-
quency, purpura, livedo, and nodules with distal gangrene
being less frequent. (e systemic form of PAN is the most
severe and 28 to 60% are accompanied by skin manifesta-
tions. (e cutaneous form of PAN, less frequent, may
present nodules (74–80%), livedo reticularis (56–74%), and
ulcerations (8–51%) [54].
2.2.5. Connective Tissue Diseases. Connective tissue diseases
such as scleroderma, lupus erythematosus, and dermato-
myositis within the group of idiopathic inflammatory my-
opathies are autoimmune diseases of unknown origin that
can affect different organs and have characteristic DMs.
(ese 3 pathologies may require admission to the ICU due to
their impact on vital organs or complications derived from
immunosuppressive treatment. However, some patients
may present diagnostic criteria for more than one specific
connective tissue disease, as in mixed connective tissue
disease (MCTD), making specific diagnosis difficult.
Scleroderma is characterized by the thickening and
adhesion of the tegument due to increased production of
collagen in the dermis, hypodermis, and some organs which
leads to fibrosis of the skin and underlying tissues. Localized
or morphea forms exist, and systemic forms can include
organ involvement.
Systemic lupus erythematosus (SLE) can affect any organ
and tissue of the body. At the cutaneous level, the most
typical manifestation is a malar rash or butterfly rash
characterized by raised erythematous lesions at the malar
level, along the nasolabial sulcus, that can be precipitated by
sun exposure and leaves no scar. Moreover, skin lesions
could be plaques with epidermal atrophy that can leave a
hypopigmented area on sun-exposed and sun-protected
areas [55].
(e main manifestations of dermatomyositis are skin
disorders and skeletal muscle weakness. One of the most
typical lesions is Gottron’s papules, present in more than
70% of cases, in the form of slightly raised lesions with a
purplish appearance that appear on the back of the meta-
carpophalangeal and interphalangeal joints. Also charac-
teristic is Gottron’s sign with macules or erythematous
plaques that are located on the back of joints such as the
elbow or knee. Other common lesions are heliotrope
erythema in the form of violet-coloured or periorbital er-
ythematous macules, periungual telangiectasias, and sym-
metrical violaceous erythema, which appear in exposed areas
such the front and back of the upper trunk, arms, or face
[56]. (e recognition of these DMs is of special interest due
to their association in more than 30% of cases with neo-
plasms, interstitial pulmonary fibrosis, and heart disease.
Autoantibodies in idiopathic inflammatory myopathies re-
search will help us identify different clinical subgroups
[57, 58].
MCTD is a rare systemic autoimmune rheumatic disease
characterized by the association of clinical manifestations of
SLE, systemic skin sclerosis, and dermatomyositis in the
presence of high levels of anti-U1-RNP antibodies. Symp-
toms at the cutaneous level are varied [59]. Raynaud’s
phenomenon is an early feature in more than 90% of pa-
tients. Sclerodactyly and nail fold vascular changes are also
common. Skin rashes may resemble lupus or dermato-
myositis. Digital infarcts may present in some patients and it
is rare that it presents as truncal scleroderma. (ese
symptoms are usually accompanied by polyarthritis, hand
oedema, myositis, and esophageal hypomotility. Treatment
is based at controlling symptoms and should be early in the
face of potentially serious manifestations such as pulmonary
hypertension. Immunosuppressive therapy and steroids
remain the therapeutic mainstay for MCTD [60].
2.3. DermatologicalManifestations Secondary to the Situation
and Management of Critical Patients. Most DMs appear
during admission to the ICU and are due to factors sur-
rounding critical patients. During the stay in the ICU,
immobilization, malnutrition, impaired tissue perfusion,
immune dysfunction, fluctuations in body temperature, or
difficulties in maintaining hygiene are factors that affect the
cutaneous barrier and favour the appearance of cutaneous
lesions [20]. We include lesions of infectious origin, from
drug reactions or secondary to the use of devices.
2.3.1. Dermatological Disorders of Infectious Origin.
Lesions secondary to an infectious agent are the most fre-
quent DMs in the intensive setting and appear in the evo-
lution of critical illness [61]. Bedding, humidity, obesity, etc.,
favour the appearance of inflammatory dermatitis in large
Figure 4: Morbilliform rash: maculopapular exanthem on the
trunk.
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skin folds, with stratum corneum damage favouring the
entry of germs such as Candida albicans or beta-haemolytic
Streptococcus bacteria.
Superficial mycosis caused by Candida is the most
common problem. It starts at the bottom of the fold
as an erythematous plaque that is wet and bright red and
well-delimited. Furrowing of the fold and the presence of
papulopustular lesions outside the erythematous plaque
(satellite lesions) are characteristic (Figure 4). (e diagnosis
is usually clinical and can be confirmed by scraping the
lesions followed by direct microscopic examination with
potassium hydroxide stain or by culture. Local treatment
with antifungal agents is usually sufficient, in addition to the
establishment of preventive measures with the routine use of
skin protectants to keep the skin clean, dry, and hydrated
[62].
2.3.2. Dermatological Disorders from Drug Reactions.
Cutaneous eruptions resulting from drug reactions in the
intensive field occur in 10% of cases. (e complexity of
critical patients, usually polytreated and with a context of
immunosuppression, favours the appearance of adverse
drug reactions at the cutaneous level. (e most frequent
form of presentation is a morbilliform rash characterized by
erythematous macules and papules, usually with symmetric
distribution, which may be confluent in plaques. (ey
predominate in the trunk and pressure areas and extend to
the extremities and face may be spared (Figure 5). (is
morbilliform eruption usually appears approximately 1 week
after starting the responsible drug and lasts between 1 or 2
weeks. (e most common drugs associated with rash are
penicillins and derivatives, sulfonamides, and anticonvul-
sants [63].
Urticaria is another rash secondary to drugs. (e rash
appears as raised lesions with a paler central area and an
erythematous halo that are produced by oedema of the
superficial dermis; urticaria is accompanied by itching. (e
lesions appear within the first 24 hours after exposure to the
responsible drug and resolve in the next 24–48 hours.
Approximately 20% of urticaria cases are accompanied by
angioedema consisting of oedema of the mucous
membranes, including the respiratory and intestinal tracts.
(e drugs commonly associated are penicillins and deriv-
atives and nonsteroidal anti-inflammatory drugs.
Treatment is based on the withdrawal of the suspect drug
and antihistamines or steroids for symptom control [36].
2.3.3. Dermatological Disorders Secondary to Devices.
Patients admitted to the ICU require advanced monitoring
and treatment that require the use of various devices, both
invasive and noninvasive, that can cause varying degrees of
DMs. Complications from the use of devices have usually
been related to their capacity to produce infection [64] or to
problems related to their placement [65, 66]. Invasive
procedures or some devices used in the monitoring or
treatment of critical patients can cause iatrogenic injuries or
inflammatory reactions that cause contact dermatitis [8].
When implanting a catheter or performing a tracheos-
tomy, for example, the skin barrier is broken, which can
cause injuries that become permanent; sometimes the in-
juries are imperceptible, but sometimes they leave an un-
sightly lesion.
Contact dermatitis is an eczematous disease due to the
inflammatory reaction of the skin to an external agent such
as antiseptics, self-adhesive electrodes, or other devices [67].
2.3.4. Dermatological Disorders-Related Pressure Injury.
Critically ill patients are at high risk of developing pressure
ulcers. Factors related to the development of these ulcers are
prolonged stay, immobility, deep sedation, use of vasoactive
drugs, hypotension, anasarca, organ dysfunction, and
malnutrition [68]. (ere are various strategies aimed at
preventing the appearance of ulcers such as the use of
pressure redistribution equipment, intense physiotherapy,
protective dressings, and trying to achieve an optimal state of
general health. However, despite use of best practice mea-
sures, pressure ulcers can occur, and their identification and
early treatment are essential for their good evolution [69].
2.3.5. Dermatological Disorders Induced by Vasopressor
Drugs. Skin necrosis can appear as a complication of the
infusion of vasopressor drugs. Classically, it is related to the
use of high doses of dopamine and norepinephrine. (e
existence of disseminated intravascular coagulation and
cardiocirculatory shock are risk factors for the development
of ischemic skins lesions that can progress to symmetrical
peripheral gangrene related to vasopressors [70]. Vaso-
pressin, useful in the treatment of catecholamine-resistant
vasodilatory shock, may also provoke cutaneous ischemia,
due to its vasoconstrictor action on the arteriolar level. (e
ischemic skin lesions are normally localized in the distal area
of the extremities and the trunk.When the administration of
vasopressin is by a peripheral vein, it may provoke local
cutaneous ischemia if it infiltrates into the subcutaneous
tissue. To avoid the potential for ischemic lesions, admin-
istration of vasopressin should be by central venous catheter,
and careful monitoring of the extremities to detect ischemic
changes should be carried out. Early recognition and prompt
Figure 5: Candida intertrigo: genitocrural intertrigo in the
inframammary fold infected by Candida albicans. Note. Satellite
lesions.
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treatment with systemic, local, or topical sympathetic
blockers or vasodilators may be beneficial in treating is-
chemia and the definitive treatment that has been estab-
lished for gangrene is amputation of ischemic limbs [71].
2.4. Previous Dermatological Disorders. Patients may pres-
ent dermatological disorders that may need to be identified
when admitted to the ICU (e.g., when a patient cannot
provide his or her medical history or information is not
available). Some chronic skin diseases such as psoriasis or
connective tissue diseases must be recognized and could be
exacerbated during admission, requiring specific treat-
ment. Other processes, such as lichen planus and atopic
eczema, may require symptomatic treatment. Other dis-
eases, due to their characteristics, may involve chronic
treatment that must be taken into account in the man-
agement of the admitted patient, or the patient may
manifest lesions unrelated to the pathology of admission
that do not require treatment but that may complicate the
evaluation of the patient, such as cutaneous tumours,
cutaneous infectious diseases, and pigmentation disorders;
in these cases, it is necessary to consult a dermatology
specialist (Figure 6).
3. Conclusions
(e present review includes the DMs that may appear in the
intensive care setting. In many cases, making it difficult to
diagnose, the patient cannot manifest clinical aspects (pain,
itching, etc.) because of sedation or neurological disorders.
(e algorithm proposed by Jack et al. can be used to
identify the most frequent DMs in ICU. In this algorithm,
DMs with vital compromise are first identified. In the next
step, differentiate the processes that appear during or before
ICU admission and determine the priorities of the con-
sultation with the dermatology specialist [72].
(e great variety of skin problems highlights the im-
portance of including a systematic examination of the skin in
ICU care routines [73].(e classification we have used de-
fines different groups of skin pathologies.
Life-threatening DMs are infrequent, but they must be
quickly recognized, and initiation of specific treatment and
maintenance at an early stage is essential. DMs associated
with systemic diseases offer the possibility of adding der-
matological signs to skin examinations that help in the
diagnosis of underlying disease. In addition, DMs that occur
during the management of critical patients must be expected
and diagnosed during daily patient care.
(e complexity of critical patients requires the collab-
oration of different health professionals. Intensive care
professionals should consult dermatologists. We must
provide comprehensive care covering any medical and
surgical pathology; therefore, detection and control of dif-
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774, 2005.
[7] M. O. Visscher, C. C.White, J. M. Jones, T. Cahill, D. C. Jones,
and B. S. Pan, “Face masks for noninvasive ventilation: fit,
excess skin hydration, and pressure ulcers,” Respiratory Care,
vol. 60, no. 11, pp. 1536–1547, 2015, http://rc.rcjournal.com/
content/60/11/1536/tab-pdf.
[8] M. Badia, J. Trujillano, L. Serviá, J. March, and A. Rodŕıguez-
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M. S. Holanda, A. Garćıa de Lorenzo, and F. Gordo, “On
behalf of the grupo de trabajo de planificación, organización y
gestión de la sociedad española de semicyuc. document on the
state of affairs of the spanish model of intensive care medicine.
SEMICYUC Strategic Plan 2018–2022,” Medicina Intensiva,
vol. 43, pp. 47–51, 2018, http://www.medintensiva.org/en-
pdf-S2173572718302030.
12 Critical Care Research and Practice
